Our team’s depth of clinical, scientific and consulting experience enables us to generate valuable insights across all sectors of the life sciences industry.
Insights that can help move your organization forward and meet current challenges with financial and strategic success. Over the past 20 years, we have built strong relationships with clients across the life sciences industry.
We utilize our talented and global network of life sciences-focused professionals to help you not only realize growth opportunities but also drive innovative strategies across all divisions of your business.
We know that implementing a strong and sustainable business strategy requires robust support throughout the entire product life cycle, from early development to launch and post-launch. Our full-service offerings include strategy development and business planning, competitive assessment, due diligence, deal execution advice and alliance management advice.
We employ a broad range of experience, from corporate and investment strategy to transaction evaluation and value creation.
We provide data-driven insights that help clients build pragmatic strategies that deliver results.
When it comes to transactions in the life sciences industry, our clients consist of traditional corporations, as well as private equity firms and their portfolio businesses.
Our team brings both deep industry knowledge and experience from a myriad of transactions.
Navigating the life sciences landscape requires a suite of industry professionals – ranging from scientists to clinicians and consultants. With this blend of perspectives, along with more than two decades of industry relationships, our team can tap into targeted resources and provide insightful, innovative services for clients across all sectors. Our experience spans the public and private sector, as well as every major therapeutic area.
We use our experience to help companies successfully navigate the evolving life sciences landscape.
Worldwide, many regions struggle to lay the foundations for a functioning health care system. A lack of basic necessities, extreme poverty and insufficient infrastructure all limit access to quality, affordable health care.
Despite significant obstacles, the world is undergoing rapid transformation. Economic conditions are improving, infrastructure is developing, and access to technology and the internet is unprecedented. With this advancement comes a new set of challenges and opportunities. Traditional emerging nation complications are increasingly well-controlled, and diseases that already plague developed nations such as diabetes and cancer are rising at alarming rates.
At EY-Parthenon Life Sciences, we advise companies, investors, institutions and governments worldwide on bringing innovative therapies, diagnostics, devices and services to patients and help them transform their health care systems in ways that are customized to their populations and the unique struggles they face. For more information, please contact our EY‑Parthenon life sciences leaders worldwide.
Worldwide, regions struggle to lay the foundations for a functioning health care system. We work with our clients to help them address their systems and the unique struggles they face.
One of Parthenon’s private equity firm clients was interested in purchasing a manufacturer of articulating ladders, sold nationally through major hardware and home improvement stores.
Parthenon was tasked with answering the private equity client’s key questions in order to confirm or deny its investment thesis. Those questions included the following:
During the six-week engagement, Parthenon used extensive primary and secondary research efforts to determine the product’s position within key retailers as well as its market penetration. Specifically, Parthenon executed interviews with several key constituencies including:
Based on the outcome of Parthenon’s work, the private equity client ultimately decided not to purchase the target company.